PRTG News and Press, Portage Biotech Inc. From 06/05/23

Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesions Based on the favorable safety and tolerability data at all doses tested to date, the Company intends to expand Phase 1 portion of the trial to evaluate higher do...

WESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that CEO Dr. Ian Walters will serve as an expert spokesperson on a...

2023-05-23 13:09:12 ET Gainers: CohBar ( CWBR ) +158% . Shuttle Pharmaceuticals ( SHPH ) +121% . Ocean Biomedical ( OCEA ) +108% . HeartCore Enterprises ( HTCR ) +110% . Lifecore Biomedical ( LFCR ) +66% . T Stamp ( IDAI ...

WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of Clin...

2023-04-24 20:19:15 ET Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently manag...

WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virt...

Portage Biotech press release ( NASDAQ: PRTG ): Q3 GAAP EPS of -$0.44 misses by $0.21 . As of December 31, 2022, the Company had cash and cash equivalents of approximately $13.1 million. For further details see: Portage Biotech GAAP EPS of -$0.44 misses by $0.21

- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, C...

Targeting Adenosine for Cancer: Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9 th @ 10:30 am ET WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology c...

WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fi...